Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine program in Florida.
Introduction of Haemophilus influenzae type b (Hib) vaccine has significantly decreased this disease's incidence in childhood. The cost-effectiveness and economic impact of the Hib immunization program in Florida were investigated and three periods compared: I = 1984-1988; II = 1989-1990; and III = 1991-1992. The cost per year of Hib disease in Period I was $27.48 million while that in Periods II and III was $15.95 million and $.88 million respectively. The total savings in millions were: Periods I and II = $11.53; Periods II and III = $11.07; and Periods I and III = $22.6. The greatest saving was realized between Periods I and III because of the initiation of immunization with the Hib vaccine starting at two months of age during Period III. Hib immunization is cost-effective and significant savings would more than pay for the cost of the program.
Midani
S
S
Pediatric Infectious Diseases and Immunology, University of Florida Health Science Center, Jacksonville, USA.
Ayoub
E M
EM
Rathore
M H
MH
D002648:Child; D002675:Child, Preschool; D003363:Cost Control; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D005431:Florida; D006192:Haemophilus Infections / Q000191:economics / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000191:economics*; D006193:Haemophilus influenzae; D006801:Humans; D007114:Immunization / Q000191:economics; D007223:Infant; D014611:Vaccination / Q000191:economics; D018074:Vaccines, Conjugate / Q000191:economics*
D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate